Refractory Solid Tumors Clinical Trial
Official title:
An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors
This study is being conducted to test study drug AZD2461 to see how it may work to treat solid tumors. The main purpose of this study is to determine the safety and tolerability of AZD2461. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00404508 -
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT02450136 -
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02596503 -
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00759928 -
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150365 -
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT00665990 -
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
|
Phase 1 | |
| Completed |
NCT02691793 -
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
|
Phase 4 | |
| Completed |
NCT02450149 -
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02691767 -
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
|
N/A | |
| Terminated |
NCT00664586 -
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05811975 -
KSX01-TCRT Injection Project in Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT03810742 -
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03096340 -
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02450123 -
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02383368 -
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
|
Phase 1 | |
| Completed |
NCT00394446 -
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03052205 -
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02482441 -
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
| Recruiting |
NCT05150457 -
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
|
Phase 1 |